J. Larkin
Oncology · with Carbonnel · 2017–2018
A researcher in the Science corpus: 2 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Oncology — 72 citations into it
Whom J. Larkin trusts
Their strongest outbound trust, strongest first, inferred from their citations.
- J. Wolchok (in Oncology)
Papers from J. Larkin's perspective
Ordered by how strongly the researchers J. Larkin trusts endorse each paper. Same corpus, a different order for every researcher.
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma (New England Journal of Medicine)
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
- Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis (Nature Communications)
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (New England Journal of Medicine)
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. (Annals of Oncology)
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody (Science Translational Medicine)
- Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (Annals of Oncology)
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
- Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)